Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12
about
Stem cells as cellular vehicles for gene therapy against glioblastomaAnti-angiogenic gene therapy in the treatment of malignant gliomasPreclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumorsIL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.Immunocompetent murine models for the study of glioblastoma immunotherapyEvaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.Current status of gene therapy for brain tumors.Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cellsGene therapy for malignant glioma.Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.The art of gene therapy for glioma: a review of the challenging road to the bedsideSystemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastasesPediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapyCombinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.Prioritization schema for immunotherapy clinical trials in glioblastoma.Strategies in gene therapy for glioblastoma.Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.Current Studies of Immunotherapy on GlioblastomaGene Delivery in Neuro-Oncology.Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.Future clinical potential of oncolytic virotherapy for pediatric CNS tumors.Tumor angiogenesis and anti-angiogenic gene therapy for cancer.Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 ExpressionAddressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy
P2860
Q26771835-5483B221-C9B5-4949-A91A-62314E41BB1FQ26866276-2B3C7860-9DDD-457B-8E38-28FD1693A4F8Q27329466-64BBC457-7729-40AE-B6E0-061670F5C80FQ30355682-415B9985-704B-4599-BB08-FE7244FBF0D6Q33574853-AFF82672-7D8E-4044-9B8D-8004A985585FQ33720628-F302FA81-9592-4582-81A9-F5DC6AB12672Q33894449-9DACC779-27B4-4044-A411-E39674BFCD7FQ34318157-E30DE964-AC58-42F5-82E9-26CA0A9CE9E0Q35126723-204BE03D-9AE4-4B9E-BBB6-6DFDB2D8F33FQ35673628-153A1CE3-1F81-4959-835D-82E2FD90374EQ36109704-5FF1BF81-0AB7-49EF-A38F-DBA83DCD4512Q36493813-CC2C93F5-0AA5-47AD-9E00-1A62AD316E7BQ36527593-6BE3B499-E568-45E7-9025-4E54B0899F72Q36544212-7287A494-7B69-4716-A508-A16A32F8914DQ36546412-16FB6A09-9D0E-4E15-90DC-30931F6F29E1Q36644898-C7D94561-0C74-4DB2-802B-743413C630CEQ36849213-F4DE41A3-51FB-484C-B039-17D81D437A69Q37031739-F44FAF63-657E-44AF-B295-E25027E2C22DQ37064326-73858B94-4BF1-4F33-93EE-2AB07C4FE24CQ37078999-A5C75D0D-206D-4888-8A0E-A3A594F6ACDCQ37420576-313BCEA3-8D80-4E5F-AD9A-EFA0D291013CQ37718569-A5B58FD5-47BB-4929-BAA9-4E9D35FF0FABQ38262914-EEBB2CB6-F614-4F90-821F-6C732A5FB518Q40060078-CDB9ADEA-48BA-482E-B616-511A91C1D15FQ42373511-764462CB-A636-4AD3-82DB-8CB50CBD713FQ44399639-E2B4B1E0-5BD3-43C9-8ABB-3ED4EA4AC9EFQ55385227-A37E760B-6977-4DC7-A189-EA960CCA4641Q58734384-11D43B87-204E-4988-8B6F-83E665A6ABF8Q58787920-EEC856B3-C077-4E8E-AE8C-C209EAE2C60B
P2860
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Preclinical evaluation of a ge ...... irus expressing interleukin-12
@ast
Preclinical evaluation of a ge ...... irus expressing interleukin-12
@en
type
label
Preclinical evaluation of a ge ...... irus expressing interleukin-12
@ast
Preclinical evaluation of a ge ...... irus expressing interleukin-12
@en
prefLabel
Preclinical evaluation of a ge ...... irus expressing interleukin-12
@ast
Preclinical evaluation of a ge ...... irus expressing interleukin-12
@en
P2093
P2860
P356
P1433
P1476
Preclinical evaluation of a ge ...... irus expressing interleukin-12
@en
P2093
Alfred D Lakeman
Debra C Quenelle
Earl R Kern
G Yancey Gillespie
Jacqueline N Parker
James J Cody
James M Markert
Jennifer M Coleman
Kathleen H Price
Richard J Whitley
P2860
P304
P356
10.1128/JVI.06998-11
P407
P577
2012-02-29T00:00:00Z